- Osiris Therapeutics (OSIR) leaps 57% after saying its stem-cell based biosurgery product Grafix closed three times as many wounds as conventional treatment in a study of patients with a diabetic foot ulcer.
- In the trial, 62% of patients receiving Grafix enjoyed complete wound closure vs only 21% who received standard care.
- Grafix also closed wounds faster and needed fewer treatments.
- Around a quarter of diabetics develop diabetic foot ulcers. (PR)
Osiris Therapeutics, Inc. (OSIR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
at Zacks.com (Nov 12, 2014)